| 2010-09-02: |
IBA Sells Prototype of Next Generation Carbon Therapy System
LOUVAIN - LA - NEUVE, Belgium, September 2, 2010 ( PRN/ots ) - IBA ( Ion Beam Applications S.A. ), developer of equipment and pharmaceuticals dedicated to cancer diagnosis and treatment, announced today that it has sold the prototype of its next generation carbon therapy system to the French company (...) |
| 2010-09-01: |
DAIICHI SANKYO Announces Enrollment in the Two Largest Single Phase III Trials so far for the Prevention of Stroke in AF and for the Treatment of VTE is Proceeding as Planned
Stockholm ( PRN/ots ) - DAIICHI SANKYO announced today that the ongoing trials ENGAGE AF - TIMI 48 ( The Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation ) and HOKUSAI VTE with their investigational factor Xa inhibitor edoxaban are enrolling in accordance to plan. The projected recruitment (...) |
| 2010-09-01: |
Largest Atrial Fibrillation Registry Reveals Poor AF Control and High Rates of Cardiovascular Hospitalization
Paris ( PRN/ots ) - Sanofi - aventis announced today that results from the RealiseAF ( Real - life global survey evaluating patients with Atrial Fibrillation ) registry show that control of atrial fibrillation ( AF ) ( defined by the 2006 ACC/AHA/ESC AF guidelines as either sinus rhythm or AF (...) |
| 2010-08-30: |
Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients
Paris, August 30, 2010 ( PRN/ots ) - Sanofi - aventis announced today that the investigational once - daily oral drug teriflunomide significantly reduced annualized relapse rate ( ARR ) at 2 years versus placebo in patients with relapsing multiple sclerosis ( RMS ), thus achieving the primary endpoint in the TEMSO (...) |
| 2010-08-29: |
Multaq( R ) First - line Option in New 2010 ESC Guidelines for the Management of Atrial Fibrillation
Paris, August 29, 2010 ( PRN/ots ) - Sanofi aventis announced today that the European Society of Cardiology ( ESC ) 2010 new Guidelines for the Management of Atrial Fibrillation ( AF ) have been released and recommend that Multaq( R ) ( dronedarone ) should be used for maintenance of sinus rhythm as (...) |
| 2010-08-17: |
Kowa Announces First EU Marketing Authorisation for Pitavastatin Granted in the UK
Wokingham, England, August 17, 2010 ( PRN/ots ) - Kowa are delighted to announce that the Medicines and Healthcare products Regulatory Agency ( MHRA ) has granted a UK licence for their statin, Livazo( R ) ( pitavastatin ). This follows the completion of the decentralized regulatory procedure, in which the MHRA (...) |
| 2010-08-17: |
Lilly Halts Development of Semagacestat for Alzheimer's Disease Based on Preliminary Results of Phase III Clinical Trials
Indianapolis, August 17, 2010 ( PRN/ots ) - Eli Lilly and Company will halt development of semagacestat, a gamma secretase inhibitor being studied as a potential treatment for Alzheimer's disease, because preliminary results from two ongoing long - term Phase III studies showed it did not slow (...) |
| 2010-08-16: |
International Society for Cellular Therapy ( ISCT ) Joins Forces With Roche and Genzyme to Launch Cell Therapy Industry Partnership
Vancouver, August 16, 2010 ( PRN/ots ) - Many companies in the cell therapy regenerative medicine market including Roche, Genzyme, Athersys, Miltenyi Biotec, Hospira, Lonza and Life Technologies will join ISCT to launch a series of new initiatives that will create greater strategic alignment within the (...) |
| 2010-08-06: |
Avastin Shows Longest Overall Survival for Patients With Adenocarcinoma, the Most Common Type of Advanced Lung Cancer
Basel, Switzerland, August 6, 2010 ( PRN/ots ) - This update outlines data from a preplanned analysis of the pivotal E4599 study in patients with non - small cell lung cancer ( NSCLC ), published in the Journal of Thoracic Oncology. The analysis looked at the impact of treatment (...) |
| 2010-08-05: |
Agendia Inaugurates New State - of - the - Art Genomics Laboratory in Irvine
Irvine, California, and Amsterdam, August 5, 2010 ( PRN/ots ) - Agendia, a world leader in molecular cancer diagnostics, today announced the inauguration of a new state - of - the - art clinical genomics laboratory in Irvine, CA. Previously, Agendia's offices and laboratory were located in Huntington (...) |
| 2010-07-22: |
Kowa Announces Successful EU Regulatory Application for Pitavastatin
Wokingham, England, July 22, 2010 ( PRN/ots ) - Kowa are delighted to announce that following the completion of the decentralized regulatory procedure, that their statin, pitavastatin has achieved a positive outcome from the UK Regulatory Authority ( MHRA ) acting as the Reference Member State for 16 (...) |
| 2010-07-15: |
Takeda Responds to FDA Advisory Committee Recommendation
London, July 15, 2010 ( PRN/ots ) - The U.S. Food and Drug Administration ( FDA ) Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee held a joint meeting primarily focused on reviewing the cardiovascular ( CV ) safety of rosiglitazone, as presented (...) |
| 2010-07-12: |
Edoxaban Demonstrates Superior Efficacy Compared With Enoxaparin Sodium in Preventing VTE After Total Knee Replacement
Tokyo, July 12, 2010 ( PRN/ots ) - Daiichi Sankyo Company, Limited announced that its investigational once - daily oral, direct factor Xa inhibitor, edoxaban, was shown to be superior to enoxaparin in preventing venous thromboembolic ( VTE ) events in patients following total knee replacement ( TKR ), a type (...) |
| 2010-07-08: |
Unprecedented Donation Made by Mrs. Lily Safra to the Institute for Brain and Spinal Cord Disorders in Paris
Paris, July 8, 2010 ( PRN/ots ) - Professor Gerard Saillant, President of the Institute for Brain and Spinal Cord Disorders ( ICM ), announced today an unprecedented donation of EUR8,000,000 from Mrs. Lily Safra. It is the largest single donation made by a private individual to the (...) |
| 2010-07-06: |
Pfizer Announces European Union Approval of a New Form of Lipitor ( atorvastatin ) for Use in Children
New York, July 6, 2010 ( PRN/ots ) - Pfizer Inc. announced it has received European Commission approval of a new chewable form of Lipitor ( atorvastatin calcium ) suitable for use in children aged 10 or older with high levels of LDL ( "bad" ) cholesterol and high triglycerides (...) |
| 2010-06-30: |
Mars hosts key scientific panel discussion at one of the largest ever gatherings of Nobel Laureates
Lindau, Germany ( na Originaltextservice ) - - Bildmaterial ist abrufbar unter http://www.presseportal.de/galerie.htx?type=obs - To tackle the world's most pressing issues, genuine collaboration between the academic community, government and industry is needed, Mars, Incorporated said yesterday. As part of (...) |
| 2010-06-28: |
Kowa Company, Ltd. Grants Abbott Exclusive Rights to Market Pitavastatin Calcium, a Lipid - lowering Drug, in Australia and New Zealand
Wokingham, England, June 28, 2010 ( PRN/ots ) - Following an enthusiastic expansion programme into new markets, Kowa Company, Ltd. ( President: Yoshihiro Miwa ), headquartered in Nagoya, Japan, has granted Abbott, headquartered in Illinois, USA the exclusive license to distribute and market pitavastatin calcium ( brand name Livalo ), (...) |
| 2010-06-28: |
New High - Resolution Computer Tomography Data Demonstrates EVISTA( R )'s Effect on Bone Quality in Osteoporotic Patients
Munich, June 28, 2010 ( PRN/ots ) - Interim data from a prospective Investigator Initiated Trial ( IIT ) presented today at the ECTS, the 37th European Symposium on Calcified Tissues, in Glasgow, demonstrates that EVISTA( R ) ( raloxifene 60mg; once - daily, distributed in 34 countries by DAIICHI SANKYO ), indicated (...) |
| 2010-06-26: |
Dapagliflozin As Add On Therapy To Insulin Demonstrated Improved Glycemic Control In Patients With Type 2 Diabetes Inadequately Controlled With Insulin
Orlando, Florida, June 26, 2010 ( PRN/ots ) - Results from a 24 - week Phase 3 clinical study demonstrated that the addition of the investigational drug dapagliflozin achieved reductions in the primary endpoint, glycosylated hemoglobin level ( HbA1c ), in inadequately controlled type 2 diabetes patients who were (...) |
| 2010-06-26: |
ONGLYZA( TM ) ( saxagliptin ) With Metformin As Initial Combination Therapy Provided 76 - Week Long - Term Glycemic Control In Treatment - Naive Adults With Type 2 Diabetes
Orlando, Florida, June 26, 2010 ( PRN/ots ) - Bristol - Myers Squibb Company and AstraZeneca today announced results up to 76 - weeks from a Phase 3 study of ONGLYZA( TM ) ( saxagliptin ) as initial combination therapy with metformin, which produced long - term glycemic improvement [as measured by glycosylated (...) |
| 2010-06-25: |
Market Demand and Innovation in Germany Propel Industrial Biotechnology Growth
Berlin ( na Originaltextservice ) - Industrial biotechnology is expected to grow worldwide by 10 to 20 percent per year through 2020. Germany has already established the preconditions to accelerate R&D and commercialization in this nascent industry, making it an ideal site for companies (...) |
| 2010-06-24: |
MDS Nordion, Guerbet, and Cyceron Announce Partnership to Develop New Diagnostic Agents
Ottawa, June 24, 2010 ( PRN/ots ) - MDS Nordion, a leading provider of products and services to the global health science market, Guerbet, a pharmaceutical group specialized in medical imaging, and Cyceron, a biomedical imaging centre in France, announced today they have entered into an (...) |
| 2010-06-24: |
Occlutech prevails in U.K. patent appeal by AGA Medical
Jena ( na Originaltextservice ) - In 2009 the Patents Court of the High Court, Chancery Division, decided that Occlutech's range of Figulla ASD and PFO occluders do not infringe the U.K. part of European Patent 0 808 138. AGA Medical decided to appeal against this (...) |
| 2010-06-22: |
Resverlogix Scientific Data Presented at EAS Congress
Hamburg and Calgary, Canada, June 22, 2010 ( PRN/ots ) - Resverlogix Corp. ( "Resverlogix" or the "Company" ) announced today that key scientific data was communicated in an oral presentation highlighting the novel features of the Company's lead drug RVX - 208 at the European Atherosclerosis Society (...) |
| 2010-06-21: |
Stallergenes: Staloral( R ) Mites 300 Clinical Study in China: Efficacy is Demonstrated
Antony, France, June 21, 2010 ( PRN/ots ) - Stallergenes S.A. announces the results of a phase III clinical trial ( VO55.06 ) conducted in China aimed at assessing the efficacy and safety of sublingual immunotherapy ( Staloral( R ) mites 300 ) in adult patients suffering from asthma triggered by house (...) |
| 2010-06-19: |
/OFF HOLD OFF HOLD OFF HOLD - - Servier/
Rome, June 19, 2010 ( PRN/ots ) - /OFF HOLD OFF HOLD OFF HOLD - Servier, PIV395527 The following release: "Protelos( R ) ( Strontium Ranelate ) Builds Stronger Bone Compared to Bisphosphonates" is now OFF HOLD. Distribution time: 19 Jun 2010 08:15 GMT The osteoporosis treatment Protelos( R ) (...) |
| 2010-06-17: |
Medtronic Announces European Launch of Protecta( TM ) Portfolio With SmartShock( TM ) Technology Shown to Significantly Reduce Inappropriate Shocks
Nice, France, June 17, 2010 ( PRN/ots ) - Medtronic, Inc. today announced European launch of the Protecta( TM ) portfolio of implantable cardioverter - defibrillators ( ICDs ) and cardiac resynchronization therapy - defibrillators ( CRT - Ds ). The implantable defibrillators feature Medtronic - exclusive SmartShock( TM ) Technology, comprised of six advanced shock - reduction algorithms that (...) |
| 2010-06-15: |
Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound / Anti - VEGF PRS - 050 is first Anticalin tested in humans
Freising - Weihenstephan ( na Originaltextservice ) - Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS - 050, an anti - VEGF Anticalin. The trial is an open - label, dose - escalating evaluation of the compound's (...) |
| 2010-06-14: |
New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non - Hodgkin Lymphoma Receiving R - CHOP Chemotherapy
Barcelona, Spain, June 14, 2010 ( PRN/ots ) - Data presented at the 15th European Hematology Association ( EHA ) congress in Barcelona, highlights the impact of febrile neutropenia ( FN ) on chemotherapy delivery in non - Hodgkin lymphoma ( NHL ) patients. The IMPACT NHL study showed that unplanned hospitalisations, delays (...) |
| 2010-06-11: |
First Dedicated Virtual Community for Immune Thrombocytopenia ( ITP ) Patients Launched Today
Zug, Switzerland, June 11, 2010 ( PRN/ots ) - Amgen ( Europe ) today launched ITPvillage.com, a dedicated website bringing together patients, healthcare professionals and those who care for people affected by ITP, at the 15th Congress of European Hematology Congress in Barcelona, Spain. For many patients living (...) |
| 2010-06-08: |
Tarceva Helps Patients With Genetically Distinct Form of Lung Cancer Live Longer
Chicago, June 8, 2010 ( PRN/ots ) - New data show that first - line treatment with Tarceva( R )( erlotinib ) delivered exceptional survival benefits in patients with advanced lung adenocarcinoma ( a form of non small cell lung cancer ) with epidermal growth factor receptor ( EGFR ) activating mutations.[1] The phase (...) |
| 2010-06-08: |
Football Stars Unite to Tackle Back Pain
Rome, June 8, 2010 ( PRN/ots ) - UK Premiership footballer Rory Delap, renowned for his devastating throw - in, has joined forces with a number of football heroes across Europe to support 'Back in Play', a European wide campaign to reach young men and women (...) |
| 2010-06-07: |
Survey Reveals Many are Ignoring Basic Measures to Check for no.1 Heart Killer Disorder in Europe
STRATFORD - UPON - AVON, England, June 7, 2010 ( PRN/ots ) - Arrhythmia Alliance, the Heart Rhythm Charity, announced today the results of a survey conducted in Europe that showed a large number of respondents ignore basic measures to check for potential cardiac arrhythmias, or heart rhythm (...) |
| 2010-06-07: |
Survey Reveals Many are Ignoring Basic Measures to Check for no.1 Heart Killer Disorder in Europe
STRATFORD - UPON - AVON, England, June 7, 2010 ( PRN/ots ) - - On World Heart Rhythm Week, Arrhythmia Alliance Launches 'Know Your Pulse' Campaign to Raise Awareness of the Importance of Pulse Checking to Keep Cardiac Conditions Under Control Arrhythmia Alliance, the Heart Rhythm (...) |
| 2010-06-07: |
Pieris AG Appoints Chief Scientific Officer
Freising - Weihenstephan ( na Originaltextservice ) - Pieris AG announced today that Laurent Audoly, Ph.D., has joined the company as Chief Scientific Officer, effective immediately. Dr. Audoly, most recently Biologics Research Site Lead at Merck & Co. Inc., brings both pharma and biotech experience, (...) |
| 2010-06-07: |
Teriflunomide in Adjunct to Interferon Beta Significantly Improved Outcomes of Multiple Sclerosis Patients
Paris, June 7, 2010 ( PRN/ots ) - Sanofi - aventis reported today new one - year data from a Phase II study with teriflunomide, a novel oral disease modifier being investigated for the treatment of relapsing multiple sclerosis ( RMS ). Study results demonstrated an improvement in outcomes, with (...) |
| 2010-06-07: |
ArQule And Daiichi Sankyo Present Final Phase 2 Results For ARQ 197 C - Met Inhibitor in Non - Small Cell Lung Cancer at ASCO
Woburn, Massachusetts and Tokyo, June 7, 2010 ( PRN/ots ) - ArQule, Inc. and Daiichi Sankyo Co., Ltd. ( TSE 4568 ) today announced the presentation of data from a Phase 2 clinical trial at the 2010 Annual Meeting of the American Society of Clinical Oncology ( ASCO ) (...) |
| 2010-06-04: |
Scientists Give the Go - Ahead for Private Storage of Stem Cells From Umbilical Cord Blood
Zutphen, Netherlands, June 4, 2010 ( PRN/ots ) - Four world - renowned stem cell experts have recently given their full support to private cordblood banking. The four scientists supported the "Family Cord Blood Bank" which has just been established in the US by CORD:USE. Cryo - (...) |
| 2010-05-28: |
Prolia( R ) ( Denosumab ) Granted Marketing Authorization in the European Union
Thousand Oaks, California, May 28, 2010 ( PRN/ots ) - Amgen Inc. today announced that the European Commission ( EC ) has granted marketing authorization for Prolia( R ) ( denosumab ) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss (...) |
| 2010-05-26: |
Your Story, Your Voice, Your Achievements, Your Ideas (...) This Is About Life, Real Life, Real MS
Geneva, May 26, 2010 ( PRN/ots ) - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced the launch of Real MS today on World MS Day 2010. Real MS, a global multiple sclerosis ( MS ) awareness campaign, aims to unite the voice of those (...) |
| 2010-05-26: |
First Major Survey of Multiple Sclerosis ( MS ) Nurses Highlights Significant Disparities in MS Nursing Across Europe
Brussels, May 26, 2010 ( PRN/ots ) - The first major survey of European Multiple Sclerosis ( MS ) nurses revealed that nearly one in three nurses ( 31 Prozent ) reported that standards of MS care are not adequately maintained in their country. The results of this survey will be (...) |
| 2010-05-25: |
NEVO( TM ) Sirolimus - Eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve - Month Data
Paris, May 25, 2010 ( PRN/ots ) - At 12 months the NEVO( TM ) Sirolimus - eluting Coronary Stent has continued to demonstrate excellent safety and efficacy outcomes compared to Taxus( R ) Liberte( R ) according to new data presented today from the NEVO( TM ) RES - I clinical trial. These results were (...) |
| 2010-05-25: |
Take a Peek at the Undercover World of Parasites
Monheim, Germany, May 25, 2010 ( PRN/ots ) - Who said that learning about bugs was boring? An amazing new journey through the wonderful world of parasites launches on YouTube today. Four exciting videos, inspired by the 'Parasites Life Undercover' exhibition at the Berlin Natural History (...) |
| 2010-05-19: |
The French Competition Authority Follows up Allegations of Anti - competitive Practices by Sanofi - Aventis to Exclude Fair Generic Competition for Plavix( R ) ( clopidogrel )
Utrecht, The Netherlands, May 19, 2010 ( PRN/ots ) - Teva Santé, one of France's leading generic medicines companies, has welcomed news that the French Competition Authority has agreed to its request to investigate alleged anti - competitive practices by Sanofi - Aventis aimed at preventing generic competition (...) |
| 2010-05-16: |
Biggest Study Ever Reports on Mobiles and Brain Cancer
Hong Kong, May 16, 2010 ( PRN/ots ) - The International Journal of Epidemiology today published a combined data analysis from a multi national population - based case - control study of glioma and meningioma, the most common types of brain tumour. This is the first in a (...) |
| 2010-05-12: |
Sanofi - aventis Initiates 10,000 Patient Study With Multaq( R ) in Permanent Atrial Fibrillation
Paris, May 12, 2010 ( PRN/ots ) - Sanofi - aventis announced today the initiation of a multinational, randomized, double - blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq( R ) ( dronedarone ) in over 10,000 patients with permanent atrial fibrillation ( AF ) to reduce major adverse (...) |
| 2010-05-03: |
BIO 2010: German Molecular Diagnostics Segment Posting Double - Digit Growth
Berlin/Chicago ( na Originaltextservice ) - Molecular diagnostics has quickly become one of the most important biotechnology segments in Germany. With an estimated 10 percent share of the EUR 2 billion German diagnostics market, the segment enjoys a compound annual growth rate of (...) |
| 2010-04-30: |
Pieris Announces Positive Preclinical Data on c - Met Anticalin Drug Program
Freising - Weihenstephan ( na Originaltextservice ) - Novel Approach with PRS - 110 Shows Dose - dependent Response in Cancer Model Pieris AG announced today preclinical data for its proprietary PRS - 110 Anticalin" compound, which targets the c - Met receptor, demonstrating a dose - dependant reduction of (...) |
| 2010-04-29: |
European Workers Would Trade Money for an Early Retirement
Rotterdam, The Netherlands, April 29, 2010 ( PRN/ots ) - The lure of retirement is simply too much for many Europeans with almost one in three workers ( 29 Prozent ) saying they would prefer their government not to raise the national retirement age, and would be happy (...) |
| 2010-04-28: |
Pitavastatin Demonstrates Sustained Efficacy, Tolerability and LDL - C Target Attainment Over 52 Weeks
Wokingham, England, April 28, 2010 ( PRN/ots ) - New long - term phase III data published today in Atherosclerosis demonstrates that, of patients with primary hypercholesterolaemia or combined dyslipidaemia who received 4mg of pitavastatin, 74 Prozent and 73.5 Prozent achieved NCEP* and EAS* low - density lipoprotein cholesterol ( LDL - (...) |
|
|
1
2
3
4
5
6
7
8
9
10
11
more...
|
